Table 1.
Clinical and treatment characteristics
| Characteristic | Patients (n) | Proportion or median (range) | ||
| Age | 74 (29–90) years | |||
| Follow-up period | 21.1 (4.3–58.2) months | |||
| Sex | Male | 40 | 58.8% | |
| Female | 28 | 41.2% | ||
| Histology | Primary lung carcinoma | Adeno carcinoma | 13 | 19.1% |
| Squamous cell carcinoma | 9 | 13.2% | ||
| Small cell carcinoma | 1 | 1.4% | ||
| Adeno squamous carcinoma | 1 | 1.4% | ||
| Metastatic tumour | 18 | 26.5% | ||
| Unknown | 26 | 38.2% | ||
| Tumour location | Upper lobe | 39 | 57.4% | |
| Middle or lower lobe | 29 | 42.6% | ||
| Peripheral | 68 | 100.0% | ||
| Central (<2 cm from mediastinum) | 0 | 0.0% | ||
| History of previous smoking | 29 | 42.6% | ||
| GTV volume | 2.8 (0.2–41.0) cm3 | |||
| PTV volume | 27.5 (4.0–149.0) cm3 | |||
| Lung volume | 2593.4 (1408.9–5627.1) cm3 | |||
| Number of SRT | Once | 58 | 92.1% | |
| Twice | 5 | 7.9% | ||
| Prescription dose | 48 Gy/4 Fx | 33 | 48.5% | |
| 50 Gy/5 Fx | 19 | 27.9% | ||
| 54 Gy/6 Fx | 1 | 1.5% | ||
| 56 Gy7 Fx | 9 | 13.2% | ||
| 56 Gy/8 Fx | 5 | 7.4% | ||
| 60 Gy/12 Fx | 1 | 1.5% |
Fx, fractions; GTV, gross tumour volume; PTV, planning target volume; SRT, stereotactic radiation therapy.